Here is the design of a clinical trial:

Official Title: The Impact of Depression and/or Anxiety on Patients With Acute Coronary Syndrome After Percutaneous Coronary Interventions

Included conditions:
- Acute Coronary Syndrome
- Depression
- Anxiety

Study Armgroups:
- {'label': 'No depression/anxiety', 'description': 'patients suffered from ACS who have undergone PCI without depression or anxiety'}
- {'label': 'Depression', 'description': 'patients suffered from post-ACS depression who have undergone PCI', 'interventionNames': ['Other: antidepressive and anti-anxiety therapy']}
- {'label': 'Anxiety', 'description': 'patients suffered from post-ACS anxiety who have undergone PCI', 'interventionNames': ['Other: antidepressive and anti-anxiety therapy']}
- {'label': 'Depression with anxiety', 'description': 'patients suffered from post-ACS depression with anxiety who have undergone PCI', 'interventionNames': ['Other: antidepressive and anti-anxiety therapy']}

Interventions:
- {'type': 'OTHER', 'name': 'antidepressive and anti-anxiety therapy', 'description': 'These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.', 'armGroupLabels': ['Anxiety', 'Depression', 'Depression with anxiety']}

Primary Outcomes:
- {'measure': 'Major Adverse Cardiovascular Events', 'description': 'death, myocardial infarction, stroke, angina pectoris, revascularization.', 'timeFrame': 'From date of first visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months'}

Please estimate the sample size based on the assumption: 
Significance level (α) of 0.05, power larger than 85%, follow-up loss rate of 20%
Sample size
        According to our preliminary research, about 20% patients with ACS post-PCI developed depression and/or anxiety [Pr(x=1)], the incidence of MACE in ACS patients without emotional disorders post-PCI was about 15% [Pr(y=1|x=0)]. We presumed conservatively that the HR of MACE in 2 years for patients with depression and/or anxiety was 1.3, and the rate of follow-up loss was approximately 20%, a total of 5000 patients would yield power larger than 85% in a two-sided test at Î± of 0.05.